Unknown

Dataset Information

0

Caloric vestibular stimulation for the management of motor and non-motor symptoms in parkinson's disease: Intention-to-treat data.


ABSTRACT: This report provides data related to the safety and effectiveness of repeated time-varying caloric vestibular stimulation (CVS) as a treatment for motor and non-motor features of Parkinson's disease (PD). Forty-six subjects receiving stable anti-Parkinsonian therapy were randomized to active (n = 23) or placebo (n = 23) treatment arms. Subjects self-administered CVS twice-daily over a period of 8 weeks at home via a portable, pre-programmed, solid-state ThermoNeuroModulation (TNM™) device delivering continually-varying thermal waveforms through aluminium ear-probes mounted on a wearable headset. Change scores from baseline to end of treatment and to a 1-month follow-up were determined using standardized clinical measures. The data presented here report sample demographics, detailed safety data and the statistical outcomes from the intention-to-treat and modified intention-to-treat analyses. These data supplement findings of the main per protocol analysis reported in the allied article entitled, 'Caloric Vestibular Stimulation for the Management of Motor and Non-Motor Symptoms in Parkinson's Disease' Wilkinson et al.

SUBMITTER: Wilkinson D 

PROVIDER: S-EPMC6661455 | biostudies-literature | 2019 Aug

REPOSITORIES: biostudies-literature

altmetric image

Publications

Caloric vestibular stimulation for the management of motor and non-motor symptoms in parkinson's disease: Intention-to-treat data.

Wilkinson David D   Podlewska Aleksandra A   Banducci Sarah E SE   Pellat-Higgins Tracy T   Slade Martin M   Bodani Mayur M   Sakel Mohamed M   Smith Lanty L   LeWitt Peter P   Ade Kristen K  

Data in brief 20190708


This report provides data related to the safety and effectiveness of repeated time-varying caloric vestibular stimulation (CVS) as a treatment for motor and non-motor features of Parkinson's disease (PD). Forty-six subjects receiving stable anti-Parkinsonian therapy were randomized to active (n = 23) or placebo (n = 23) treatment arms. Subjects self-administered CVS twice-daily over a period of 8 weeks at home via a portable, pre-programmed, solid-state ThermoNeuroModulation (TNM™) device delive  ...[more]

Similar Datasets

| S-EPMC5386963 | biostudies-literature
| S-EPMC8599939 | biostudies-literature
| S-EPMC5074346 | biostudies-literature
| S-EPMC6857726 | biostudies-literature
| S-EPMC4787111 | biostudies-literature
| S-EPMC6439208 | biostudies-literature
| S-EPMC8381736 | biostudies-literature
| S-EPMC8137296 | biostudies-literature
| S-EPMC5560285 | biostudies-other
| S-EPMC5088323 | biostudies-other